S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
New CBOE “special perk” helps traders target income every weekend (Ad)
Why do tech stocks go down when interest rates rise?
Own Dollar General? Hurry and take this advice before earnings
New CBOE “special perk” helps traders target income every weekend (Ad)
Pure Storage stock fumbles for a rare buying opportunity
Black Swan: this small cap surged over 1000% last week
All the trading advice you’ve ever received boils down to this (Ad)
AppLovin (APP): Losing its shareholders lovin'?
Snowflake’s bullish tailwind is turning into a gale-force wind
S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
New CBOE “special perk” helps traders target income every weekend (Ad)
Why do tech stocks go down when interest rates rise?
Own Dollar General? Hurry and take this advice before earnings
New CBOE “special perk” helps traders target income every weekend (Ad)
Pure Storage stock fumbles for a rare buying opportunity
Black Swan: this small cap surged over 1000% last week
All the trading advice you’ve ever received boils down to this (Ad)
AppLovin (APP): Losing its shareholders lovin'?
Snowflake’s bullish tailwind is turning into a gale-force wind
S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
New CBOE “special perk” helps traders target income every weekend (Ad)
Why do tech stocks go down when interest rates rise?
Own Dollar General? Hurry and take this advice before earnings
New CBOE “special perk” helps traders target income every weekend (Ad)
Pure Storage stock fumbles for a rare buying opportunity
Black Swan: this small cap surged over 1000% last week
All the trading advice you’ve ever received boils down to this (Ad)
AppLovin (APP): Losing its shareholders lovin'?
Snowflake’s bullish tailwind is turning into a gale-force wind
S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
New CBOE “special perk” helps traders target income every weekend (Ad)
Why do tech stocks go down when interest rates rise?
Own Dollar General? Hurry and take this advice before earnings
New CBOE “special perk” helps traders target income every weekend (Ad)
Pure Storage stock fumbles for a rare buying opportunity
Black Swan: this small cap surged over 1000% last week
All the trading advice you’ve ever received boils down to this (Ad)
AppLovin (APP): Losing its shareholders lovin'?
Snowflake’s bullish tailwind is turning into a gale-force wind

G1 Therapeutics Stock Price, News & Analysis (NASDAQ:GTHX)

$2.00
0.00 (0.00%)
(As of 12/4/2023 ET)
Compare
Today's Range
$1.93
$2.11
50-Day Range
$1.12
$2.00
52-Week Range
$1.08
$8.40
Volume
871,055 shs
Average Volume
905,050 shs
Market Capitalization
$103.68 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.80

G1 Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
490.0% Upside
$11.80 Price Target
Short Interest
Bearish
4.80% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.45
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.96) to ($0.82) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.82 out of 5 stars

Medical Sector

725th out of 952 stocks

Pharmaceutical Preparations Industry

342nd out of 434 stocks


GTHX stock logo

About G1 Therapeutics Stock (NASDAQ:GTHX)

G1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing trilaciclib, a (CDK) 4/6 inhibitor can protect bone marrow and reduce hematologic adverse events (AEs), as well as improve emerging treatments through myeloprotection which improve patients' overall anti-tumor immune responses combination with the antibody-drug conjugate; and treatment of neoadjuvant breast cancer. In addition, the company develops lerociclib, an oral CDK4/6 inhibitor for multiple oncology indications; and rintodestrant, an oral selective estrogen receptor degrader, and HER2-negative breast cancer. The company has a license agreement with EQRx, Inc. and Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat any indication in humans, as well as Nanjing Simcere Dongyuan Pharmaceutical Co., LTD. for the development and commercialization of trilaciclib for any indication in humans through parenteral delivery, and ARC Therapeutics for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.

GTHX Stock Price History

GTHX Stock News Headlines

New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Earnings Preview For G1 Therapeutics
G1 Therapeutics Q3 2023 Earnings Preview
G1 Therapeutics earnings: here's what Wall Street expects
See More Headlines
Receive GTHX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for G1 Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/01/2023
Today
12/04/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/06/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GTHX
Employees
170
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$11.80
High Stock Price Target
$19.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+490.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
6 Analysts

Profitability

Net Income
$-147,560,000.00
Pretax Margin
-87.36%

Debt

Sales & Book Value

Annual Sales
$51.30 million
Book Value
$1.60 per share

Miscellaneous

Free Float
47,577,000
Market Cap
$103.68 million
Optionable
Optionable
Beta
1.81
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. John E. Bailey Jr. (Age 58)
    CEO, President & Director
    Comp: $1.06M
  • Mr. Mark Avagliano (Age 47)
    Chief Business Officer
    Comp: $628.54k
  • Mr. John W. Umstead V (Age 38)
    Chief Financial Officer
  • Mr. Terry L. Murdock (Age 63)
    Chief Operating Officer
    Comp: $541.59k
  • Mr. William C. Roberts (Age 54)
    Vice President of Investor Relations & Corporate Communications
  • Ms. Monica R. Thomas
    General Counsel & Chief Compliance Officer
  • Mr. Evan Hicks M.B.A.
    Vice President of Marketing
  • Dr. Rajesh K. Malik Ch.B. (Age 64)
    M.B., M.D., Chief Medical Officer
    Comp: $596.37k
  • Mr. Andrew Perry (Age 50)
    Chief Commercial Officer
    Comp: $568.6k
  • Mr. Jeff Macdonald
    Senior Director of Investor Relations & Corporate Communications














GTHX Stock Analysis - Frequently Asked Questions

Should I buy or sell G1 Therapeutics stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for G1 Therapeutics in the last year. There are currently 1 sell rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" GTHX shares.
View GTHX analyst ratings
or view top-rated stocks.

What is G1 Therapeutics' stock price target for 2024?

6 equities research analysts have issued 1-year price objectives for G1 Therapeutics' stock. Their GTHX share price targets range from $5.00 to $19.00. On average, they predict the company's stock price to reach $11.80 in the next year. This suggests a possible upside of 490.0% from the stock's current price.
View analysts price targets for GTHX
or view top-rated stocks among Wall Street analysts.

How have GTHX shares performed in 2023?

G1 Therapeutics' stock was trading at $5.43 at the start of the year. Since then, GTHX stock has decreased by 63.2% and is now trading at $2.00.
View the best growth stocks for 2023 here
.

When is G1 Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 6th 2024.
View our GTHX earnings forecast
.

How were G1 Therapeutics' earnings last quarter?

G1 Therapeutics, Inc. (NASDAQ:GTHX) released its quarterly earnings results on Wednesday, November, 1st. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.31) by $0.04. The firm earned $12.30 million during the quarter, compared to analysts' expectations of $13.73 million. G1 Therapeutics had a negative trailing twelve-month return on equity of 132.03% and a negative net margin of 90.82%.

What other stocks do shareholders of G1 Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other G1 Therapeutics investors own include Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), Johnson & Johnson (JNJ), Gilead Sciences (GILD), Kadmon (KDMN), VBI Vaccines (VBIV), Novavax (NVAX) and Pfizer (PFE).

When did G1 Therapeutics IPO?

(GTHX) raised $101 million in an IPO on Wednesday, May 17th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Cowen and Company acted as the underwriters for the IPO and Needham & Company and Wedbush PacGrow were co-managers.

Who are G1 Therapeutics' major shareholders?

G1 Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Raymond James & Associates (1.79%), Jacobs Levy Equity Management Inc. (1.11%), Connor Clark & Lunn Investment Management Ltd. (0.39%), Denali Advisors LLC (0.29%), Acadian Asset Management LLC (0.25%) and Franklin Street Advisors Inc. NC (0.16%). Insiders that own company stock include Andrew Perry, James S Hanson, Jennifer K Moses, John E (Jack) Jr Bailey, Mark A Velleca, Mark A Velleca, Rajesh Malik, Seth Rudnick and Terry L Murdock.
View institutional ownership trends
.

How do I buy shares of G1 Therapeutics?

Shares of GTHX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:GTHX) was last updated on 12/5/2023 by MarketBeat.com Staff

My Account -